medwireNews: Temporarily withholding adjuvant endocrine therapy (ET) to attempt pregnancy does not adversely impact the short-term disease outcomes of women with hormone receptor-positive early breast cancer, indicate POSITIVE data.
medwireNews: Interim analysis of the monarchE trial indicates that the invasive disease-free survival (iDFS) benefits of adding adjuvant abemaciclib to endocrine therapy have strengthened after 4 years of follow-up in patients with high-risk, hormone receptor-positive, HER2-negative, early breast cancer.
medwireNews: Non-Hispanic Black women with hormone receptor-positive, HER2-negative, early breast cancer have worse outcomes than their non-Hispanic White counterparts despite similar genetic risk and treatment adherence in the first year, suggests an analysis of the RxPONDER trial.
medwireNews: The 21-gene expression assay may be a poor prognostic aid for premenopausal women aged less than 40 years with luminal B subtype, hormone receptor-positive, HER2-negative early breast cancer, indicates research presented at the ESMO Asia Congress 2022 in Singapore.
medwireNews: Analysis of the monarchE trial suggests that an increase in the burden of diarrhea is the only patient-reported outcome (PRO) to be adversely affected by the addition of abemaciclib to standard endocrine therapy (ET) in Chinese patients with hormone receptor-positive, HER2-negative, node-positive early breast cancer.
medwireNews: Dose-dense adjuvant chemotherapy significantly improves the outcomes of individuals with node-positive, early-stage breast cancer relative to the standard schedule, confirm the end-of-study findings from GIM2 presented at the ESMO Congress 2022 in Paris, France.
medwireNews: The 10-year findings from the DATA trial have shown no significant benefit of extending aromatase inhibitor (AI) treatment beyond 5 years of sequential therapy in the full study population of postmenopausal women with hormone receptor-positive breast cancer.
medwireNews: The monarchE investigators have identified baseline factors linked to an increased risk for discontinuation of abemaciclib in the trial comprising patients with hormone receptor-positive, HER2-negative early breast cancer.
medwireNews: Plasma circulating tumor (ct)DNA analysis could help identify patients with hormone receptor (HR)-positive, HER2-negative early breast cancer who are likely to have distant recurrence at 5 years or more after diagnosis despite receipt of adjuvant therapy, indicate CHiRP study results.
medwireNews: Combining clinicopathologic factors with the luminal A subtype could help identify women with a very low risk for breast cancer local recurrence after breast-conserving surgery, making them good candidates for adjuvant radiotherapy omission, suggests the LUMINA study.